Drug Story

→ WHAT IT COVERS Tim Harford traces the rise of Lydia Pinkham's Vegetable Compound, a 20% alcohol herbal tonic marketed to women in the 1870s-1900s, examining why unproven patent medicines dominated American healthcare, how demand grew 20 times faster than the economy, and how public outrage eventually created the FDA. → KEY INSIGHTS - **Quackery economics:** Between 1810 and 1939, inflation-adjusted spending on unproven patent medicines grew 20 times faster than the US economy as a whole.

→ WHAT IT COVERS Cardiologist Eric Topol joins Drug Story host Thomas Getz to examine why pharmacogenomics has failed to reach clinical practice 20 years after the Human Genome Project, how the Vioxx scandal exposed pharmaceutical accountability gaps, and what evidence-based longevity science actually supports versus what supplement sellers promote. → KEY INSIGHTS - **Pharmacogenomics Gap:** Over 150 FDA-approved drugs carry genomic labels that could guide safer dosing or prevent fatal...

→ WHAT IT COVERS Drug Story examines Ambien (zolpidem), the most prescribed sleeping pill in US history, through Caroline's firsthand account of sleepwalking, blackouts, and relationship damage, alongside psychiatrist Dr. Andrew Crystal's analysis of why insomnia treatment remains flawed and why Cognitive Behavioral Therapy outperforms medication for chronic sufferers.

→ WHAT IT COVERS Drug Story examines chronic pain, affecting 50 million Americans, through patient Paul's 15-year ordeal, the history of pain medicine from John Bonica's 1953 textbook through the opioid crisis, and the 2025 FDA approval of Journavix, the first new non-opioid pain drug in two decades. → KEY INSIGHTS - **Chronic Pain Neuroscience:** Chronic pain is not an ongoing injury but a central nervous system malfunction where nerve receptors become permanently oversensitized, creating a...

→ WHAT IT COVERS Author John Green and journalist Dan Weissman examine how Johnson & Johnson used secondary drug patents to restrict access to bedaquiline, a tuberculosis drug, affecting an estimated 1.4 million patients annually. India's Section 3D patent law, two TB survivors' legal victory, and Green's nerdfighter community combined to pressure J&J into expanding generic access.

→ WHAT IT COVERS This episode examines how testosterone replacement therapy transformed from rare medical treatment for serious testicular dysfunction into a mainstream lifestyle intervention used by 14% of men over 40. It traces pharmaceutical marketing that rebranded normal aging as "Low T," creating a billion-dollar industry despite limited evidence of benefits beyond sexual function and mood.

→ WHAT IT COVERS Xanax (alprazolam) transformed anxiety treatment after its 1981 approval, offering instant relief but creating widespread dependency. The episode traces anxiety from ancient philosophy to modern diagnosis, examines how benzodiazepines replaced dangerous barbiturates, and reveals why Xanax prescriptions now carry FDA black box warnings about addiction, overdose risk, and dangerous withdrawal symptoms.

→ WHAT IT COVERS This episode examines how GLP-1 drugs like Ozempic transformed obesity treatment by addressing it as a medical disease rather than a willpower issue. The narrative connects Norman Borlaug's Green Revolution and cheap grain production to ultra-processed foods, the obesity epidemic affecting 100 million Americans, and how these medications work by eliminating food cravings while costing $10,000-$17,000 annually per patient.

→ WHAT IT COVERS Sertraline (Zoloft) is America's most prescribed antidepressant, taken by eight million people. The episode examines how SSRIs work (or don't), why the "chemical imbalance" theory is oversimplified, and why most patients must try multiple drugs before finding one that helps their depression. → KEY INSIGHTS - **Trial and error reality:** The STAR-D study of 3,000 patients found only fifty percent responded to their first or second antidepressant.

→ WHAT IT COVERS Lipitor (atorvastatin) became history's most profitable drug, generating $125 billion by treating high cholesterol to prevent heart disease. The episode examines how Framingham Heart Study established cholesterol as a risk factor, how statins were discovered from Japanese mold research, and why 90 million Americans now take these drugs despite controversial evidence about their actual benefit for prevention.

→ WHAT IT COVERS The EpiPen's transformation from a $200 million product to a $2 billion blockbuster reveals how a century-old emergency allergy treatment became controversial through price increases from $100 to $700. The episode exposes how official medical guidance to avoid allergens in infants actually caused the food allergy epidemic affecting 10% of children today.

→ WHAT IT COVERS Drug Story podcast trailer introduces a series examining modern diseases and pharmaceutical treatments. Host Thomas Goetz explores how medications manage symptoms without addressing root causes, featuring patient stories and expert analysis of the disease business and drug effectiveness. → KEY INSIGHTS - **Treatment versus cure paradigm:** Pharmaceutical medications manage disease symptoms and help patients cope with conditions, but rarely address underlying causes of illness.